TG Therapeutics, Inc.
IT ˙ BIT ˙ US88322Q1085
34,00 € 0,00 (0,00%)
2026-06-05
DEL PRIS
SecurityIT:1TGTX / TG Therapeutics, Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership340,900 shares
Latest Disclosed Value $ 11,324,698
Renaissance Technologies Llc ownership in 1TGTX / TG Therapeutics, Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 340,900 shares of TG Therapeutics, Inc. (IT:1TGTX) valued at $9,429,294 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 13, 2025 disclosing 0 shares of TG Therapeutics, Inc.. The current value of the position is $11,590,600 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F TG THERAPEUTICS COM 88322Q108 340,900 340,900 11,325 0.0177
2025-08-13 2025-06-30 13F TG THERAPEUTICS COM 88322Q108 0 -168,594 -100.00 0 -100.00
2025-05-14 2025-03-31 13F TG THERAPEUTICS COM 88322Q108 168,594 168,594 6,648 0.0101
2024-11-13 2024-09-30 13F TG THERAPEUTICS COM 88322Q108 0 -309,371 -100.00 0 -100.00
2024-08-09 2024-06-30 13F TG THERAPEUTICS COM 88322Q108 309,371 -531,229 -63.20 5,504 45,758.33 0.0093
2024-05-13 2024-03-31 13F TG THERAPEUTICS COM 88322Q108 840,600 1,400 0.17 13 -14.29 0.0201
2024-02-13 2023-12-31 13F TG THERAPEUTICS COM 88322Q108 839,200 -537,262 -39.03 14 27.27 0.0222
2023-11-14 2023-09-30 13F TG THERAPEUTICS COM 88322Q108 1,376,462 840,262 156.71 12 -15.38 0.0196
2023-08-11 2023-06-30 13F TG THERAPEUTICS COM 88322Q108 536,200 536,200 13 0.0192
2023-05-12 2023-03-31 13F TG THERAPEUTICS COM 88322Q108 0 -99,100 -100.00 0 -100.00
2023-02-13 2022-12-31 13F TG THERAPEUTICS COM 88322Q108 99,100 -80,100 -44.70 1 -99.91 0.0016
2022-11-14 2022-09-30 13F TG THERAPEUTICS COM 88322Q108 179,200 -1,001,900 -84.83 1,061 -78.86 0.0015
2022-08-12 2022-06-30 13F TG THERAPEUTICS COM 88322Q108 1,181,100 983,500 497.72 5,020 167.16 0.0059
2022-05-13 2022-03-31 13F TG THERAPEUTICS COM 88322Q108 197,600 -51,600 -20.71 1,879 -60.32 0.0022
2022-02-11 2021-12-31 13F TG THERAPEUTICS COM 88322Q108 249,200 249,200 4,735 0.0059
2021-11-12 2021-09-30 13F TG THERAPEUTICS COM 88322Q108 0 -145,800 -100.00 0 -100.00
2021-08-13 2021-06-30 13F TG THERAPEUTICS COM 88322Q108 145,800 11,800 8.81 5,656 -12.43 0.0071
2021-05-13 2021-03-31 13F TG THERAPEUTICS COM 88322Q108 134,000 -234,000 -63.59 6,459 -66.26 0.0080
2021-02-10 2020-12-31 13F TG THERAPEUTICS COM 88322Q108 368,000 269,400 273.23 19,143 625.39 0.0208
2020-11-13 2020-09-30 13F TG THERAPEUTICS COM 88322Q108 98,600 -1,056,800 -91.47 2,639 -88.27 0.0026
2020-08-13 2020-06-30 13F TG THERAPEUTICS COM 88322Q108 1,155,400 643,600 125.75 22,507 346.92 0.0194
2020-05-14 2020-03-31 13F TG THERAPEUTICS COM 88322Q108 511,800 -667,700 -56.61 5,036 -61.53 0.0049
2020-02-13 2019-12-31 13F TG THERAPEUTICS COM 88322Q108 1,179,500 1,070,706 984.16 13,092 2,042.72 0.0101
2019-11-13 2019-09-30 13F TG THERAPEUTICS COM 88322Q108 108,794 -51,706 -32.22 611 -55.98 0.0005
2019-08-12 2019-06-30 13F TG THERAPEUTICS COM 88322Q108 160,500 114,400 248.16 1,388 274.12 0.0012
2019-05-14 2019-03-31 13F TG THERAPEUTICS COM 88322Q108 46,100 -829,800 -94.74 371 -89.67 0.0003
2019-02-12 2018-12-31 13F TG THERAPEUTICS COM 88322Q108 875,900 523,400 148.48 3,591 81.91 0.0039
2018-11-13 2018-09-30 13F TG THERAPEUTICS COM 88322Q108 352,500 352,500 1,974 0.0020
2016-02-11 2015-12-31 13F TG THERAPEUTICS COM 88322Q108 0 0 0 0.0000
2015-08-14 2015-06-30 13F TG THERAPEUTICS COM 88322Q108 0 -19,399 -100.00 0 -100.00
2015-05-13 2015-03-31 13F TG THERAPEUTICS COM 88322Q108 19,399 -138,482 -87.71 300 -88.00 0.0006
2015-02-13 2014-12-31 13F TG THERAPEUTICS COM 88322Q108 157,881 146,682 1,309.78 2,501 2,001.68 0.0060
2014-11-12 2014-09-30 13F TG THERAPEUTICS COM 88322Q108 11,199 11,199 119 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.